Jean Franchi

Ms Franchi have more than 20 years of experience in building and leading senior corporate and divisional financial teams from the research and development stage through product launch and commercial operations. Her experience spans both the public and private pharmaceutical, biotech, and diagnostics sectors. She is currently the Chief Financial Officer of Replimune Group Inc a biotechnology company developing oncolytic immuno-gene therapies for the treatment of cancer. Prior to Replimune, She served as the Chief Financial Officer of Merrimack Pharmaceuticals, Dimension Therapeutics and Good Start Genetics. She also spent 16 years at Genzyme Corporation, a US-based biotechnology company now owned by Sanofi S.A., where she was instrumental in preparing the company for its transition from early market introductions to becoming the industry leader in rare disease drug development and commercialization. Prior to Genzyme, she worked in accounting, finance, and sales operations for two diagnostic companies: bioMerieux, Inc., and API, a former division of American Home Products (now Pfizer). She is a chair of the Risk committee.